RecitalsPurchase Agreement • February 7th, 2003 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
EXHIBIT 99.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of this 27th day of November, 2002 by and among TRINITY BIOTECH PLC, a corporation organized under the laws of the Republic of...Registration Rights Agreement • February 7th, 2003 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
EXHIBIT 99.3 NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS...Trinity Biotech PLC • February 7th, 2003 • In vitro & in vivo diagnostic substances • New York
EXHIBIT 4b.2 LEASE AGREEMENT BETWEEN RONAN O'CAOIMH AND JIM WALSH WITH TRINITY BIOTECH MANUFACTURING LIMITED IN RESPECT OF OFFICE PREMISES IN BRAY, CO WICKLOW, IRELAND THIS INDENTURE made the 26 day of November 2004 B E T W E E N RONAN O'CAOIMH of...Lease Agreement • March 31st, 2006 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
1 THIS AGREEMENT is made on 31 October, 1996. BETWEEN: (1) ENVIROMED PLC is a company incorporated in England and Wales (Registered No. 2815159) and having its registered office at Mercury House, 195 Knightsbridge, London SW7 1YE ("Enviromed"); (2)...Agreement • December 9th, 1996 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • England
WARRANTTrinity Biotech PLC • February 7th, 2003 • In vitro & in vivo diagnostic substances • New York
EXHIBIT 99.2 NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS...Trinity Biotech PLC • February 7th, 2003 • In vitro & in vivo diagnostic substances • New York
AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS Deposit Agreement Dated as of October 21, 1992 As Amended and Restated as of _______________, 2004Deposit Agreement • January 15th, 2004 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
DEPOSIT AGREEMENT dated as of October 21, 1992, as amended and restated as of _____________, 2004 among Trinity Biotech plc, incorporated under the laws of the Republic of Ireland (herein called the Issuer), THE BANK OF NEW YORK, a New York banking corporation (herein called the Depositary), and all Owners and holders from time to time of American Depositary Receipts issued hereunder.
Exhibit A to Deposit AgreementTrinity Biotech PLC • January 15th, 2004 • In vitro & in vivo diagnostic substances
The Bank of New York as depositary (hereinafter called the "Depositary"), hereby certifies that _____________________________________________________________ ___________________________________________________, or registered assigns IS THE OWNER OF ___________________________
Amended and Restated Credit Agreement and GuarantyCredit Agreement • February 22nd, 2023 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
WARRANTTrinity Biotech PLC • February 7th, 2003 • In vitro & in vivo diagnostic substances • New York
LEASE AGREEMENTLease Agreement • March 25th, 2015 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
LORRELLE S. JOHNSON and SHARON L. JOHNSON, of 3094 North Main Street Extension, Jamestown, New York 14701, hereinafter referred to as “Johnson,”
JOINT FILING AGREEMENT and POWER OF ATTORNEYJoint Filing Agreement • October 17th, 2008 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
The undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including any amendments thereto) with respect to the American Depository Receipts of Trinity Biotech plc beneficially owned by each of them to the extent that they may be deemed to be acting as a group, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. The undersigned further agree that each of them is (i) individually eligible to use the Schedule 13D to which this Exhibit is attached and (ii) responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness of accuracy of the information concerning any other person making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Joint Filing Agreement may be executed in any n
First Amendment to Amended and Restated Credit Agreement and GuarantyTrinity Biotech PLC • April 24th, 2023 • In vitro & in vivo diagnostic substances • New York
This First Amendment to Amended and Restated Credit Agreement and Guaranty, dated as of April 20, 2023 (this “First Amendment”), is entered into by and among TRINITY BIOTECH, INC., a Delaware corporation (“U.S. Holdings”), FITZGERALD INDUSTRIES INTERNATIONAL, INC., a Delaware corporation (“U.S. Fitzgerald”), CLARK LABORATORIES, INC. (d/b/a Trinity Biotech (USA)), a New York corporation (“U.S. Clark”), BIOPOOL U.S., INC., a Delaware corporation (d/b/a Trinity Biotech Distribution), (“U.S. Biopool”), PRIMUS CORPORATION, a Missouri corporation (“U.S. Primus”), MARDX DIAGNOSTICS, INC., a California corporation (“U.S. Mardx”), IMMCO DIAGNOSTICS, INC., a Delaware corporation (“U.S. Immco” and together with U.S. Holdings, U.S. Fitzgerald, U.S. Clark, U.S. Biopool, U.S. Primus and U.S. Mardx, each a “Borrower” and collectively, the “Borrowers”), the Guarantors party hereto, the Lenders party hereto and PERCEPTIVE CREDIT HOLDINGS III, LP, a Delaware limited partnership, as Lender and as adminis
AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • April 9th, 2014 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of July 26, 2013 by and among: (i) IMMCO Diagnostics, Inc., a Delaware corporation (the “Company”); (ii) Trinity Biotech PLC, an Irish public limited company (“Parent”), (iii) Trinity Biotech, Inc., a Delaware corporation (the “Buyer”); (iv) TRIB Acquisition Corp., a Delaware corporation (“Merger Sub”); and (v) Summit Partners Venture Capital Fund II-A, L.P., Summit Partners Venture Capital Fund II-B, L.P., and Summit Investors VI, L.P., each a Delaware limited partnership (collectively, “Summit Partners”), solely in their collective capacity as the Representative hereunder.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 11th, 2022 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:
SHARE PURCHASE AGREEMENT between Goldcup 7149 AB, changing name to Trinity Biotech Sweden AB and et al regarding the shares in Fiomi Diagnostics ABShare Purchase Agreement • April 6th, 2012 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
ContractEmployment Agreement • May 16th, 2023 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
This Employment Agreement (this "Agreement") is entered into as of October 3, 2022 between Aris Kekedjian ("Employee") and Trinity Biotech, Inc. ("Trinity" or the "Company").
STOCK PURCHASE AGREEMENTStock Purchase Agreement • June 16th, 2004 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED AT THE APPROPRIATE PLACES WITH FIVE ASTERISKS [*****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIALTransition Agreement • April 30th, 2024 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
TRANSITION AGREEMENT (this “Agreement”), dated as of December 20, 2023, among Bayer Healthcare LLC, a Delaware limited liability company (“Bayer”), WaveForm Technologies, Inc. a Delaware corporation (“WaveForm”), and TRIB Biosensors Inc., a Delaware corporation (“Trinity”).
TRINITY BIOTECH INVESTMENT LIMITED, as Issuer TRINITY BIOTECH PLC, as Guarantor WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee 4.00% Exchangeable Senior Notes due 2045 INDENTURE Dated as of April 9, 2015Trinity Biotech PLC • April 9th, 2015 • In vitro & in vivo diagnostic substances • New York
INDENTURE, dated as of April 9, 2015, among Trinity Biotech Investment Limited, an exempted limited liability company incorporated under the laws of the Cayman Islands, as issuer (the “Company”), Trinity Biotech plc, a public limited company incorporated under the laws of Ireland, as Guarantor (the “Guarantor”), and Wilmington Trust, National Association, a national banking association, as trustee (the “Trustee”).
SUBLEASE AGREEMENTSublease Agreement • March 25th, 2015 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
THIS SUBLEASE AGREEMENT, made and entered into on December 1, 2007 by and between 60 PINEVIEW LLC, organized and existing under and by virtue of the laws of the state of New York having its principal office at 60 Pineview Drive, Amherst, New York 14228 (the “Sublessor”) and IMMCO DIAGNOSTICS, INC., organized and existing under and by virtue of the laws of the State of New York with its address at 60 Pineview Drive, Amherst, New York 14228 (the “Sublessee”).
WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES REPRESENTED BY AMERICAN DEPOSITARY RECEIPTS TRINITY BIOTECH PLCTrinity Biotech PLC • December 23rd, 2021 • In vitro & in vivo diagnostic substances • New York
This Warrant is issued pursuant to that certain Credit Agreement and Guaranty dated as of December 15, 2021 (the “Credit Agreement”) by and among Trinity Biotech, Inc., a Delaware corporation (“U.S. Holdings”), Fitzgerald Industries International, Inc., a Delaware corporation (“U.S. Fitzgerald”), Clark Laboratories, Inc. (d/b/a as Trinity Biotech (USA)), a New York corporation (“U.S. Clark”), MarDx Diagnostics, Inc., a California corporation (“U.S. MarDx”), Biopool U.S., Inc., a Delaware corporation (d/b/a Trinity Biotech Distribution) (“U.S. Biopool”), Primus Corporation, a Missouri corporation (“U.S. Primus”), IMMCO Diagnostics, Inc., a Delaware corporation (“U.S. Immco” and together with U.S. Holdings, U.S. Fitzgerald, U.S. Clark, U.S. Mardx, U.S. Biopool and U.S. Primus, each a “Borrower” and collectively, the “Borrowers”), certain guarantors party thereto from time to time, the lenders from time to time party thereto, and Perceptive Credit Holdings III, LP, as administrative agent
INVESTOR SUBORDINATION AGREEMENTInvestor Subordination Agreement • April 30th, 2024 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
THIS SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of May 3, 2022, by and among MICO IVD HOLDINGS, LLC, as Subordinated Lender party to the Junior Convertible Note described below (including its successors and assigns in such capacity from time to time, the “Subordinated Lender”) and PERCEPTIVE CREDIT HOLDINGS III, LP, as agent for the Senior Lenders party to the Senior Credit Agreement described below (including its successors and assigns in such capacity from time to time, the “Senior Agent”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIALAsset and Share Purchase Agreement • February 1st, 2024 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
ASSET AND SHARE PURCHASE AGREEMENT, dated as of January 30, 2024, among TRIB Biosensors Inc., a Delaware corporation (“Buyer”), WaveForm Technologies, Inc., a Delaware corporation (“Waveform”), WaveForm Holdings, LLC, a Delaware limited liability company (“Parent,” and, together with Waveform, the “Sellers”), and Waveform EU d.o.o., a Slovenian company with the registration number: 8868450000, with its business address at Obrtna cesta 18, 8310 Šentjernej, Slovenia (“Sub,” and, together with the Sellers, the “Companies”).
WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES REPRESENTED BY AMERICAN DEPOSITARY RECEIPTS TRINITY BIOTECH PLCTrinity Biotech PLC • April 30th, 2024 • In vitro & in vivo diagnostic substances • New York
This Warrant is issued pursuant to that certain Credit Agreement and Guaranty dated as of December 15, 2021 (the “Credit Agreement”) by and among Trinity Biotech, Inc., a Delaware corporation (“U.S. Holdings”), Fitzgerald Industries International, Inc., a Delaware corporation (“U.S. Fitzgerald”), Clark Laboratories, Inc. (d/b/a as Trinity Biotech (USA)), a New York corporation (“U.S. Clark”), MarDx Diagnostics, Inc., a California corporation (“U.S. MarDx”), Biopool U.S., Inc., a Delaware corporation (d/b/a Trinity Biotech Distribution) (“U.S. Biopool”), Primus Corporation, a Missouri corporation (“U.S. Primus”), IMMCO Diagnostics, Inc., a Delaware corporation (“U.S. Immco” and together with U.S. Holdings, U.S. Fitzgerald, U.S. Clark, U.S. Mardx, U.S. Biopool and U.S. Primus, each a “Borrower” and collectively, the “Borrowers”), certain guarantors party thereto from time to time, the lenders from time to time party thereto, and Perceptive Credit Holdings III, LP, as administrative agent
PATENT LICENSE AGREEMENTPatent License Agreement • March 25th, 2015 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • Massachusetts
This PATENT LICENSE AGREEMENT (the “Agreement”) is entered into as of August 3, 2006, by and between Inverness Medical Innovations, Inc., a corporation organized and existing under the laws of Delaware (hereinafter called “Inverness”), and Trinity Biotech PLC, a corporation organized and existing under the laws of the Republic of Ireland (hereinafter called “Trinity”).
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT-NONEXCLUSIVE COVER PAGEPatent License Agreement • March 25th, 2015 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • District of Columbia
US Patent 8,148,057, entitled, “Immunoassays and Devices for Detection of Anti-Lipoidal Antibodies”, issued 4/3/2012, claiming priority to US Provisional Patent Application No. 60/693,120, filed 6/21/2005, inventor, Arnold Castro.
BUSINESS & ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 25th, 2015 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • England
PATENT LICENSE AGREEMENTAgreement • March 25th, 2015 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • Texas
THIS AGREEMENT (“Agreement”) is between the Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, and Trinity Biotech, Incorporated, a Missouri corporation having a principal place of business located at1930 Business Center Drive, Saint Louis, Missouri 63114, USA (“Trinity”).
EXECUTION VERSION TRINITY BIOTECH PLC AND CERTAIN OF ITS AFFILIATES STAGO INTERNATIONAL S.A.S. PURCHASE AND SALE AGREEMENT for the sale and purchase of the diagnostic coagulation business of Trinity MARCH 10, 2010Purchase and Sale Agreement • April 14th, 2011 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances
Trinity Biotech Plc, a public limited company incorporated in Ireland (registered number 183476) whose registered office is at IDA Business Park, Bray, Co. Wicklow, Ireland (“Trinity”);
THIS INDENTURE made the 20 day of December 2007 B E T W E E NTrinity Biotech PLC • March 25th, 2015 • In vitro & in vivo diagnostic substances
RONAN O’CAOIMH of Glencarrig, Delgany, County Wicklow and JIM WALSH of Ardvana, The Hill, Monkstown, Co. Dublin (hereinafter called “the Landlord”) which expression shall where the context so admits include their respective successors in title, executors, administrators and assigns) of the one part TRINITY BIOTECH MANUFACTURING LIMITED having its registered office at IDA Business park, Bray, County Wicklow (hereinafter called “the Tenant” which expression shall where the context so admits include its successors in title and permitted assigns) of the other part and
Second Amended and Restated Credit Agreement and GuarantyTrinity Biotech PLC • February 1st, 2024 • In vitro & in vivo diagnostic substances • New York
ASSET PURCHASE AGREEMENT by and among BENEN TRADING LTD. EDWARD FITZGERALD KEVIN FITZGERALD and FITZGERALD INDUSTRIES INTERNATIONAL, INC. April 15, 2004Asset Purchase Agreement • June 16th, 2004 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
THIS AGREEMENT is made as of April 15, 2004 by and between BENEN TRADING LTD., an Irish limited company (“Buyer”) FITZGERALD INDUSTRIES INTERNATIONAL, INC., a Massachusetts corporation (“Seller”), Mr. EDWARD FITZGERALD and Mr. KEVIN FITZGERALD (“Shareholders”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 11th, 2022 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of this ● day of April, 2022 by and among Trinity Biotech plc, a public limited company incorporated under the laws of Ireland (“Company”), and certain persons listed on Schedule A hereto (such persons, in their capacity as holders of Registrable Securities (as defined below), the “Holders” and each a “Holder”).
